Immutep's NSCLC Trial Shows Strong Survival Data, but TACTI-004 Failure Raises Questions — Immutep Limited

Event summary

Immutep's INSIGHT-003 trial showed a median overall survival (mOS) of 30.9 months in first-line non-squamous NSCLC patients, outperforming historical benchmarks.
The TACTI-004 Phase III trial was discontinued after failing to show superiority over the control arm in objective response rate (ORR).
Preliminary immune monitoring data from TACTI-004 revealed a different immune activation profile compared to previous studies.
Root cause analysis for TACTI-004 is ongoing, with additional results expected in Q3 2026.

The big picture

Immutep's positive survival data from INSIGHT-003 highlights the potential of eftilagimod alfa in NSCLC, but the failure of TACTI-004 underscores the challenges in replicating success across different trial settings. The biotech sector continues to grapple with the unpredictability of immunotherapy combinations, where early-phase promise does not always translate into Phase III success. Immutep's ability to navigate this discrepancy will be critical for its long-term viability.

What we're watching

Clinical Strategy Shift: Whether Immutep can pivot its clinical strategy based on the root cause analysis of TACTI-004 to revive efti's development.
Regulatory Pathways: The pace at which Immutep can secure new regulatory pathways or partnerships following the mixed trial results.
Investor Confidence: How investors will react to the contrasting outcomes of INSIGHT-003 and TACTI-004, particularly given efti's Fast Track designation.